Press Coverage
Sofinnova Capital
Henrijette Richter discusses R&D in plenary at WuXi Global Forum
Related Deal lead
Henrijette RichterRelated Strategy
CapitalHenrijette Richter, managing partner at Sofinnova Partners, participated in the opening plenary panel discussion at the WuXi Global Forum 2022 on January 10. Marking the 10th anniversary of the event, the panel, led by Jorge Conde, general partner at Andreessen Horowitz, took a look back at 10 years of breakthroughs that are changing the game in R&D productivity before turning their focus on the future. Henrijette joined David Berry, founder and CEO of Valo Health; Diego Miralles, CEO of Laronde, and Roger Perlmutter, chairman and CEO of Eikon Therapeutics.
View the replay here.
Related News
Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline
Elevara Medicines appoints biotech veteran as CEO
Tenpoint Therapeutics Announces United Kingdom YUVEZZI™ Submission of Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults
Seven years: the journey behind Myricx's acquisition by Novartis
Sofinnova Partners announces Myricx Bio agrees to be acquired by Novartis